Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan

Enliven Therapeutics CEO Samuel Kintz sold 2,270 shares of common stock at an average price of $27.5573, executed under a pre-arranged 10b5-1 trading plan.

Summary

• On July 31, 2024, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 2,270 shares of common stock.
• The sale was executed at a weighted average price of $27.5573 per share, with individual trades ranging from $27.50 to $27.655.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following the transaction, Kintz directly owns 1,061,255 shares.
• Kintz also indirectly owns shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
• He disclaims beneficial ownership of shares held by irrevocable trusts for his two sons, dated October 26, 2021, as he has no control over these trusts.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports a routine stock sale under a pre-existing trading plan. There's no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often executed under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The size and frequency of these sales can be indicative of management's confidence in the company's future prospects, although they can also be driven by personal financial planning needs.

Comparison to Industry Standards

• Executive stock sales are a routine part of compensation and wealth management in publicly traded companies.
• Companies like Pfizer, Amgen, and Eli Lilly also see regular Form 4 filings from their executives.
• The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations, similar to what executives at companies like Moderna and BioNTech employ.
• The scale of the sale (2,270 shares) is relatively small compared to the total shares beneficially owned (1,061,255), suggesting it's likely part of a planned diversification strategy rather than a major shift in sentiment.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the relatively small size of the sale suggests the impact will be minimal.
• The sale does not directly impact employees, customers, suppliers, or creditors.

Key Dates